Alkane Resources Ltd (ASX:ALK) has built its cash pile to $432 million and is now proposing to pay a maiden dividend as a result.

Strong production bolsters balance sheet

The company said in a statement to the ASX that its cash holdings increased by $104 million for the quarter, allowing it to initiate the new capital management plan.

Alkane said it produced 42,491 ounces of gold equivalent for the quarter at an all-in sustaining cost of $3011 per ounce, bringing full year gold production to 168,337 ounces.

The company said it expected gold production for the current year to come in at 163,000-177,000 ounces of gold equivalent at an all-in sustaining cost of $2900-$3200 per ounce.

Managing director Nic Earner said it was a good end to the year for the company.

It has been another great quarter for Alkane, producing 40,949 ounces of gold and 456 tonnes of antimony (42,491 ounces of gold equivalent) over the full quarter, which places full year FY26 production at 168,337 ounces of gold equivalent, in the top half of guidance. Our site operating cashflow was $174 million for the quarter, resulting in a balance sheet with $454 million in cash, bullion and listed investments at quarter end. Reflecting this strong financial position and our confidence in the business, the Board has proposed Alkane’s first ever dividend of 2 cents per share, fully franked — a significant milestone for the Company and a tangible return to the shareholders who have supported our growth.

Exploration success building for the future

Alkane also recently announced more exploration success at its Costerfield operation in central Victoria.

The company said on 14 July it had drilled 91 holes targeting the Brunswick South Deposit and the drilling had identified a high-grade antimony and gold grade connection between the recently discovered gold dominant zone at depth and the historical surface workings.

The company added:

Drilling is continuing to identify extensions to the deeper gold dominant zone (Kiwi zone) with recent geological interpretation indicating the setting for mineralisation is similar to that of the Youle deposit currently being mined.

Mr Earner said regarding the results:

Focused extension and infill drilling at Brunswick South over the previous year has produced highly encouraging results. This newly defined deposit not only contains pockets of high gold endowment, but critically a significant quantity of antimony. Excitingly Brunswick South can be brought online without extensive access requirements as it is situated 200m from existing development. We are commencing development towards Brunswick South in the current quarter and are looking to establish it as a primary production source for Costerfield.

Alkane is valued at $1.78 billion.

The post This ASX gold miner has just proposed a maiden dividend payment appeared first on The Motley Fool Australia.

More reading

• 13 ASX 200 shares that doubled in value in FY26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Since hitting multi-year highs back in March, it has been a steady decline for ASX gold stock Regis Resources Ltd (ASX: RRL). 

It is an established multi-mine gold producer and one of the largest ASX-listed gold producers with an all-Australian asset base. 

The Duketon Gold Project (located in the Laverton region of WA) is RRL’s flagship project. 

Rollercoaster for gold stocks 

Like many other ASX gold stocks, it enjoyed a surge into early 2026 as the gold price climbed to record highs. 

This was driven by strong safe-haven demand, expectations of lower interest rates in major economies, central bank buying, and investor optimism that miners’ profits and cash flows would increase. 

However, like much of the sector, Regis Resources shares have since fallen as gold prices retreated from their peaks, and investors rotated into riskier assets amid improving market sentiment. 

Since peaking at over $9.40 per share in March, it has now fallen over 40% and is now sitting at around $5.65 per share. 

However, this ASX gold stock is now generating broker interest. 

Yesterday, the team at Bell Potter updated their outlook on Regis Resources, which included a retained buy recommendation and strong upside. 

Here’s what the broker had to say. 

FY27 guidance lifted

Late last week, Regis Resources released an updated FY27 outlook. 

As Laura Steward reported, the company lifted its FY27 production guidance, aiming for 360,000–400,000 ounces of gold at a group all-in sustaining cost of $2,990–$3,390 per ounce.

Bell Potter said this production is similar to FY26. 

Higher production at Duketon should offset slightly lower production at Tropicana. 

Costs are expected to rise because the company is mining more expensive ounces and facing higher diesel costs. 

Ramelius is also increasing spending on mine development and exploration, which should support future growth but will lift capital spending in FY27.

Healthy upside for ASX gold stock

Based on this guidance, Bell Potter retained its buy recommendation on this ASX gold stock. 

However the broker has lowered its price target to $8.45 (previously $9.45). 

However, from yesterday’s closing price, this still indicates an upside of almost 50%. 

Overall, we remain positive towards RRL’s all-Australian, multi-mine asset portfolio, leverage to the gold price and its fully unhedged, debt free position. However, higher costs and CAPEX cut our NPV-based valuation 11%, to $8.45/sh. We retain our Buy recommendation.

Bell Potter isn’t the only expert tipping a rebound for gold stocks.

Recently, the VanEck published a report suggesting many ASX gold shares remain attractively valued after the recent pullback.

The post Broker jumps on board this quality ASX gold stock and tips 50% upside appeared first on The Motley Fool Australia.

More reading

• Which ASX gold stock has Macquarie tipped to jump more than 20%?
• 5 things to watch on the ASX 200 on Tuesday
• Regis Resources upgrades FY27 production guidance and cost outlook
• Buy, hold, sell: Regis Resources, Mineral Resources, Woolworths shares
• Regis Resources steps back from Vault Minerals bid, secures break fee

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

These three ASX healthcare stocks have staged a remarkable comeback in recent weeks.

The latest recovery follows a brutal 12 months for the sector.

The S&P/ASX 200 Health Care Index (ASX: XHJ) fell 39% over the year to a nine-year low on 3 June 2026. Since then, the sector has bounced roughly 20% in a single month.

The broader S&P/ASX 200 Index (ASX: XJO) has risen just 0.1% over the same period.

So which stocks deserve a spot on your watchlist right now?

Let’s take a look at three.

Why ASX healthcare stocks are rebounding

Healthcare was the worst-performing sector on the ASX in FY26.

Why? A stronger Australian dollar, higher costs, and regulatory uncertainty all weighed on returns.

When a sector falls that far that fast, bargain hunters tend to circle, and that is exactly what has been happening since early June.

Institutional investors have rotated out of resources and into beaten-down healthcare names.

Here are three ASX healthcare stocks riding that recovery.

Pro Medicus

Pro Medicus Ltd (ASX: PME) is one of the highest-quality software businesses on the ASX.

The company’s Visage platform helps hospitals view, manage, and share medical images.

Over the last year, PME shares have been on a wild ride.

Shares sank to a 52-week low of $107.75 on 24 February before rebounding sharply. In good news for the company, the recovery has largely been fuelled by a run of new contract wins and renewals.

Brokers remain optimistic, too.

According to Morgans, the broker has reaffirmed an accumulate rating and $230.00 price target on Pro Medicus shares. Citi is even more upbeat, with a buy rating and a $240 target.

Telix Pharmaceuticals

Telix Pharmaceuticals Ltd (ASX: TLX) is the ASX’s flagship radiopharmaceutical company.

The company develops targeted radiation products to image and treat cancer.

Unfortunately, the stock has been volatile over the past year, but there is plenty happening beneath the surface.

Telix has struck a strategic radiopharma collaboration with US biotech Regeneron under which the two companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies on a 50/50 cost-and-profit-sharing basis. Under this deal, Telix will gain access to Regeneron’s antibody platform. Telix will also be able to expand its reach in solid-tumour radiopharma without bearing the full development burden itself

The company also has several FDA catalysts in 2026, led by the resubmitted NDA for TLX101-Px, branded Pixclara, an investigational PET imaging agent for glioma that the FDA accepted in April.

Perhaps as a result, management has guided to FY26 revenue of US$950 million to US$970 million.

For investors comfortable with greater levels of risk, Telix is an intriguing option among ASX healthcare stocks.

CSL

CSL Ltd (ASX: CSL) is the giant of these three ASX healthcare stocks.

The blood products and vaccines business lost around half its value over the past year, a de-rating that has wiped out years of gains.

However, the tide may be turning.

CSL shares have surged about 35% since their early-June low to $122.89.

Broker views remain split.

Morgans has a buy rating and $147.59 price target on CSL shares, whilst the consensus target sits near $140.15, implying roughly 14% upside.

The key test for CSL shares comes with the FY26 result on 19 August.

Foolish takeaway for ASX healthcare stocks

These three ASX healthcare stocks each tell a different story.

Pro Medicus offers quality and momentum. Telix offers pipeline optionality. CSL offers a potential turnaround at a beaten-down price.

All three carry risk, and recoveries can stall.

But for investors hunting the next leg of the rebound, these ASX healthcare stocks are well worth watching.

The post Top 3 ASX healthcare stocks to watch appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• CSL vs Telstra shares, which should I buy?
• I’d listen to Warren Buffett and buy cheap ASX shares
• Buy, hold, sell: Weebit Nano, Metals X, Pro Medicus shares
• Down 50%+: Are these ASX healthcare shares finally worth buying?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.